Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

European Myeloma Network Sequential Phase I / Phase II Trial on RIC Allogeneic Transplantation: an Optimized Program for High Risk Relapsed Patients

NCT01460420 is registered in ClinicalTrials.gov with European Myeloma Network B.V. as lead sponsor.

NCT NCT01460420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01460420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
European Myeloma Network Sequential Phase I / Phase II Trial on RIC Allogeneic Transplantation: an Optimized Program for High Risk Relapsed Patients
Lead sponsor
European Myeloma Network B.V.
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2011
Completion date
June 29, 2017
Enrollment
49 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic malignancies, multiple myeloma